L
Lu Daopei Medical
Renowned hematology specialist and pioneer of Chinese bone marrow transplantation
About Lu Daopei Medical
Lu Daopei Medical Group is a private healthcare provider in China specializing in hematology. The company was founded in 2012 by Professor Lu Daopei, a globally recognized hematologist and an academician of the Chinese Academy of Engineering, who is considered a pioneer in blood disease treatment and hematopoietic stem cell transplantation (HSCT) in the region. Professor Lu, born in 1931, dedicated his career to hematology after graduating from Tongji Medical College in 1955. His journey includes performing Asia's first syngeneic bone marrow transplant in 1964 and China's first allogeneic bone marrow transplant in 1981, establishing him as a foundational figure in the field. The medical group was the culmination of his life's work, established when he was in his eighties to focus on the treatment, research, and teaching of hematology and oncology. The company is now controlled by his grandson, Lu Xiaodan.
The group operates a network of specialist hospitals, including Hebei Yanda Lu Daopei Hospital, Beijing Lu Daopei Hospital Yizhuang Campus, and Beijing Lu Daopei Hospital Shunyi Campus. Expansion plans include a new hospital in Shanghai and the relocation and expansion of the Hebei facility. As of 2022, Lu Daopei Medical was the largest hematology medical service provider in China by revenue, holding a 6.4% market share. The company's business model is centered on providing comprehensive, full-cycle medical services for blood diseases. Revenue is generated from general hospital services—both inpatient and outpatient—and specialized hematological examination services. The primary source of income is inpatient services, which account for over 70% of total revenue. Its target clients are patients diagnosed with hematological disorders, including complex and refractory cases, for whom HSCT is often a crucial treatment option.
Lu Daopei Medical offers a wide array of treatments, including HSCT, chemotherapy, targeted therapy, and immunotherapy, with a significant focus on bone marrow transplants. The group is particularly noted for its high volume of HSCT procedures, completing 8,966 transplants by September 2023, the majority being the complex allogeneic and haploidentical types. This specialization makes it the second-largest HSCT participant in China. A key service is its advanced CAR-T cell therapy, positioning the hospital as a leading center for this treatment globally. The hospitals are equipped with advanced medical and laboratory equipment, including numerous clean rooms for transplant patients. The company also provides its specialized testing services to over 100 other hospitals in China.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2020 | $72M | $288M | Investcorp · Temasek | — |
| FundingOther financing | Jan 2014 | $0 | — | CBC Group | ↗ |
Growth signals
Latest recorded traffic for Lu Daopei Medical is 210 monthly website visits, down 61.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
XeratausUsing a new approach toward design, development, and technologies to offer determined innovation for Healthcare Advancements |
Miami, United States | Operational | 1 | $50M | $100M |
Clairvoyant TherapeuticsProvides evidence-based psychedelic therapy to help patients live healthier and enriched lives |
Vancouver, Canada | Acquired | |||
OrchidGenetic testing solutions for personalized health risk assessment and family planning |
San Francisco, United States | Operational | |||
SeriTechInnovative Health and Skin Care |
Barcelona, Spain | Operational | |||
Mimosa TherapeuticsOffering research-grade natural psilocybin and drug potency test kits |
United States | Operational | |||
CG OncologyFocused on developing bladder cancer therapeutics |
Irvine, United States | Operational | |||
AntegenesGenetic tests for personalized cancer risk prevention |
Tartu, Estonia | Operational | |||
GLX AnalytixBringing personalized medicine to your health care |
Copenhagen, Denmark | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lu Daopei Medical in the Dongcheng District ecosystem
The Lu Daopei Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Temasek
Investcorp
Other known investors1 additional known investor
CBC Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lu Daopei Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lu Daopei Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









